According to reports, the dispute centers on the terms of a repricing provision in the current contract.
Two healthcare giants—the insurer Anthem and the pharmacy benefits manager Express Scripts—are in court today after Anthem filed suit against its vendor, seeking damages for “pharmacy pricing that is higher than competitive benchmark pricing.”
Anthem’s suit also seeks damages related to operational issues and asks for the right to end its contract with Express Scripts, according to a statement from Anthem. However, the statement added, “Anthem has not made any decision whether to end its contract with Express Scripts at this time.”
The suit was filed in US District Court in the Southern District of New York.
Express Scripts said the giant PBM, the nation’s largest, believed the Anthem suit “is without merit,” according to a statement from a company spokesman, Brian Henry.
“Express Scripts values its relationship with Anthem and will continue to honor its commitments under the contract, as we would do with any client. Express Scripts has consistently acted in good faith and in accordance with the terms of its agreement with Anthem,” the statement said.
According to Reuters, Anthem has been seeking $3 billion in annual savings through a repricing provision in its 10-year deal with Express Scripts. Express Scripts agreed that the contract called for a repricing provision, which took effect January 1, 2016, but Express Scripts does not agree it owes $3 billion. The contract runs through 2019.
Seeking Alpha reported that Express Scripts' George Paz said he had "no clue" where Anthem derived the $3 billion figure.
The repricing provision would allow Anthem to avoid paying too much for drugs based on market prices.
Escalating prescription drug costs have captured the attention of leading presidential candidates and members of Congress. Discounts negotiated by PBMs like Express Scripts are intended to be passed on to payers and ultimately the consumer.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More